Ideaya Biosciences Inc (IDYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ideaya Biosciences Inc (IDYA) Earnings: Report Dates and Results
Ideaya Biosciences (IDYA) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Ideaya Biosciences reported EPS of -$1.22, above the -$1.26 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IDYA has an expected report date of Feb 15, 2027.
Earnings History
Of the 30 quarters below that had an estimate, IDYA beat 16, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $10.24M, down 95.1% from $207.83M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.22 | -$1.26 | -$1.42 - -$0.84 | +3.17% | Beat | -191.7% | 14 | 1 up, 11 down | Nov 3, 2026 | $10.24M |
| Jun 30, 2026 | -$1.22 | -$1.18 | -$1.27 - -$0.75 | -3.39% | Miss | N/A | 13 | 1 up, 11 down | Aug 4, 2026 | $8.86M |
| Mar 31, 2026 | -$1.11 | -$0.98 | -$1.13 - -$0.79 | -13.27% | Miss | N/A | 14 | 1 up, 1 down | May 5, 2026 | $6.56M |
| Dec 31, 2025 | -$0.94 | -$0.95 | -$1.19 - -$0.70 | +1.05% | Beat | N/A | 17 | 0 up, 2 down | Feb 17, 2026 | $10.88M |
| Sep 30, 2025 | $1.33 | -$0.55 | -$0.95 - $1.48 | +341.82% | Beat | N/A | 15 | 0 up, 0 down | Nov 4, 2025 | $207.83M |
| Jun 30, 2025 | -$0.88 | -$0.79 | -$0.90 - -$0.67 | -11.39% | Miss | N/A | 12 | 1 up, 0 down | Aug 5, 2025 | N/A |
| Mar 31, 2025 | -$0.82 | -$0.69 | -$0.86 - -$0.59 | -18.84% | Miss | N/A | 7 | 1 up, 1 down | May 6, 2025 | N/A |
| Dec 31, 2024 | -$1.49 | -$0.62 | -$0.72 - -$0.41 | -139.36% | Miss | N/A | 11 | 3 up, 4 down | Feb 13, 2025 | $7.00M |
| Sep 30, 2024 | -$0.60 | -$0.63 | -$0.79 - -$0.47 | +4.76% | Beat | N/A | 13 | 0 up, 0 down | Nov 4, 2024 | N/A |
| Jun 30, 2024 | -$0.68 | -$0.53 | -$0.63 - -$0.41 | -28.30% | Miss | N/A | 12 | 3 up, 0 down | Aug 6, 2024 | N/A |
| Mar 31, 2024 | -$0.53 | -$0.50 | -$0.63 - -$0.44 | -6.00% | Miss | N/A | 11 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.52 | -$0.46 | -$0.66 - -$0.30 | -13.04% | Miss | N/A | 10 | 0 up, 0 down | Feb 20, 2024 | $3.92M |
| Sep 30, 2023 | -$0.46 | -$0.50 | -$0.77 - -$0.25 | +8.00% | Beat | -1250.0% | 11 | 0 up, 0 down | Nov 7, 2023 | $8.04M |
| Jun 30, 2023 | -$0.50 | -$0.55 | -$0.76 - -$0.47 | +9.09% | Beat | N/A | 11 | 0 up, 0 down | Aug 10, 2023 | $3.54M |
| Mar 31, 2023 | -$0.49 | -$0.54 | -$0.69 - -$0.08 | +9.26% | Beat | N/A | 9 | 0 up, 0 down | May 9, 2023 | $7.88M |
| Dec 31, 2022 | -$0.50 | -$0.56 | -$0.73 - -$0.46 | +10.71% | Beat | N/A | 9 | 0 up, 0 down | Mar 7, 2023 | $4.02M |
| Sep 30, 2022 | $0.04 | -$0.62 | -$0.79 - -$0.51 | +106.45% | Beat | N/A | 8 | 0 up, 0 down | Nov 8, 2022 | $29.70M |
| Jun 30, 2022 | -$0.57 | -$0.51 | -$0.72 - -$0.38 | -11.76% | Miss | N/A | 7 | 0 up, 0 down | Aug 15, 2022 | $5.85M |
| Mar 31, 2022 | -$0.36 | -$0.42 | -$0.59 - -$0.17 | +14.29% | Beat | N/A | 9 | 0 up, 1 down | May 10, 2022 | $11.36M |
| Dec 31, 2021 | -$0.47 | -$0.31 | -$0.59 - -$0.04 | -51.61% | Miss | N/A | 9 | N/A | Mar 15, 2022 | $2.96M |
| Sep 30, 2021 | -$0.31 | -$0.31 | -$0.56 - $0.00 | 0.00% | In line | N/A | 9 | N/A | Nov 15, 2021 | $8.98M |
| Jun 30, 2021 | -$0.33 | -$0.08 | -$0.54 - $0.98 | -312.50% | Miss | N/A | 9 | N/A | Aug 10, 2021 | $8.76M |
| Mar 31, 2021 | -$0.28 | -$0.36 | -$0.57 - $0.05 | +22.22% | Beat | N/A | 8 | N/A | May 10, 2021 | $7.25M |
| Dec 31, 2020 | -$0.18 | -$0.30 | -$0.64 - $0.11 | +40.00% | Beat | N/A | 9 | N/A | Mar 23, 2021 | $10.57M |
| Sep 30, 2020 | -$0.17 | $1.13 | -$0.61 - $3.08 | -115.04% | Miss | N/A | 9 | N/A | Nov 12, 2020 | $8.97M |
| Jun 30, 2020 | -$0.59 | -$0.62 | -$0.66 - $4.32 | +4.84% | Beat | N/A | 7 | N/A | Aug 12, 2020 | N/A |
| Mar 31, 2020 | -$0.59 | -$0.58 | -$0.63 - -$0.50 | -1.72% | Miss | N/A | 7 | N/A | May 12, 2020 | N/A |
| Dec 31, 2019 | -$0.53 | -$0.57 | -$0.69 - -$0.45 | +7.02% | Beat | N/A | 6 | N/A | Mar 24, 2020 | N/A |
| Sep 30, 2019 | -$0.54 | -$0.66 | -$0.77 - -$0.57 | +18.18% | Beat | N/A | 5 | N/A | Nov 13, 2019 | N/A |
| Jun 30, 2019 | -$0.52 | -$0.64 | -$0.71 - -$0.55 | +18.75% | Beat | N/A | 3 | N/A | Aug 12, 2019 | N/A |
| Mar 31, 2019 | -$1.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 24, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.31, after -$3.30 the year before. It was -$3.35 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.31 | N/A |
| Dec 31, 2024 | -$3.30 | N/A |
| Dec 31, 2023 | -$1.97 | N/A |
| Dec 31, 2022 | -$1.39 | N/A |
| Dec 31, 2021 | -$1.39 | N/A |
| Dec 31, 2020 | -$1.53 | N/A |
| Dec 31, 2019 | -$3.35 | N/A |
Frequently Asked Questions About IDYA
When is Ideaya Biosciences's next earnings date?
Ideaya Biosciences's next earnings report is expected for Feb 15, 2027.
Did IDYA beat earnings estimates last quarter?
Yes. Ideaya Biosciences reported EPS of -$1.22 for the quarter ended Sep 30, 2026, above the -$1.26 estimate, a 3.17% surprise.
What EPS do analysts expect from IDYA next quarter?
The consensus EPS estimate for Ideaya Biosciences for the quarter ending Dec 31, 2026 is -$1.25 from 17 analysts, with estimates from -$1.42 to -$0.87.
How often does IDYA beat earnings estimates?
Ideaya Biosciences beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +19.97%.
IDYA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors